RxDoctor Payments Data

David Taragin, MD

Neurology · Silver Spring, MDNPI 1730151986

Payments from drug & device makers

$51,134in general payments, 2019–2025

Across 1,426 payments — averaging $35.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$25K
  • AbbVie$9K
  • Biogen$1K
  • Lundbeck LLC$1K
  • Banner Life Sciences, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $12K from 54 others

What the payments were for

  • Consulting fees$4502%
  • Speaking & faculty fees$1,3976%
  • Food & beverage$20,90792%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis218$24,749
AbbVie(2 entities)155$8,779
Biogen74$1,459
Lundbeck LLC114$1,421
Banner Life Sciences, LLC24$1,214
Teva Pharmaceuticals USA, Inc.73$1,049
Lilly USA, LLC85$1,010
UCB, Inc.58$975
EMD Serono, Inc.46$811
Sunovion Pharmaceuticals Inc.53$719
Pfizer56$710
Genentech USA, Inc.36$665
Amgen(2 entities)31$651
Acadia Pharmaceuticals Inc40$577
Bristol Myers Squibb50$574
Eisai Inc.36$560
Sanofi19$355
ANI Pharmaceuticals, Inc.5$305
Impel Pharmaceuticals Inc.17$280
AstraZeneca(2 entities)11$267
Adamas Pharmaceuticals, Inc.16$245
Neurocrine Biosciences, Inc.15$242
Biohaven Pharmaceutical Holding Company Ltd.25$206
Biohaven Pharmaceuticals, Inc.18$190
Neurelis, Inc.7$181
Acorda Therapeutics, Inc10$179
Upsher-smith Laboratories LLC9$177
Livanova USA, Inc.10$170
Amneal Pharmaceuticals LLC7$154
Kyowa Kirin, Inc.7$123
E.r. Squibb & Sons, L.L.C.7$114
Avion Pharmaceuticals7$114
Avadel CNS Pharmaceuticals, LLC5$106
Ipsen Biopharmaceuticals, Inc6$105
Argenx US, Inc.4$105
Harmony Biosciences LLC3$101
Xeris Pharmaceuticals, Inc.4$99
Sumitomo Pharma America, Inc.6$88
Johnson & Johnson(2 entities)4$77
MDD US Operations, LLC5$75
Axsome Therapeutics, Inc.3$73
Grifols USA, LLC3$72
Averitas Pharma Inc.2$66
Azurity Pharmaceuticals, Inc.1$66
Jazz Pharmaceuticals Inc.2$66
Vanda Pharmaceuticals Inc.3$66
Alnylam Pharmaceuticals Inc.3$65
Currax Pharmaceuticals LLC4$65
Tanabe Pharma America, Inc.3$61
Abbott2$52
Otsuka America Pharmaceutical, Inc.2$51
Cycle Pharmaceuticals Inc2$48
Octapharma USA, Inc.2$46
TG Therapeutics, Inc.1$41
Avanir Pharmaceuticals, Inc.2$31
Supernus Pharmaceuticals, Inc.2$29
Mallinckrodt Hospital Products Inc.1$29
Takeda Pharmaceuticals U.S.A., Inc.1$26
Vertical Pharmaceuticals, LLC2$26
Merz North America, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,134 in reported general payments places this provider in the 85th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$388,481
Medicare patients
928
Services billed
2,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$97,628
NuplazidPimavanserin Tartrate13$64,970
RytaryCarbidopa/Levodopa22$44,165
Memantine Hcl ErMemantine Hcl143$19,668
NeurontinGabapentin14$10,842
Nortriptyline Hcl298$7,791
Donepezil Hcl517$7,651
Carbidopa-LevodopaCarbidopa/Levodopa119$5,855
TegretolCarbamazepine14$5,645
Primidone196$5,526
Gabapentin176$5,499
Memantine Hcl79$4,643
Levetiracetam94$4,109
Pyridostigmine Bromide51$3,283
Propranolol Hcl ErPropranolol Hcl25$2,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$242$97,62812 claims
Acadia Pharmaceuticals IncNuplazid$577$64,97013 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$154$47,44873 claims
PfizerDilantin$710$1,82412 claims
Upsher-smith Laboratories LLCTopiramate$177$98957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 442 neurology providers in Maryland.

Other neurology in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →